The US Food and Drug Administration has given de novo authorization to Medtronic plc and Cosmo Pharmaceuticals N.V.’s GI Genius endoscopy module. The device is the first of its kind to use artificial intelligence to help detect lesions during a colonoscopy, which could have major implications for fighting colon cancer.
The agency announced on 12 April that it had granted marketing authorization to the product, which has been trained to...
Welcome to Medtech Insight
Create an account to read this article
Already a subscriber?